CTS Posts 67% Cash Flow Jump in Q2

Core Insights - CTS reported Q2 2025 results with non-GAAP EPS of $0.57 and GAAP revenue of $135.3 million, reflecting a year-over-year revenue increase of 3.8% from $130.2 million in Q2 2024 [1][2] - The adjusted gross margin improved by 2.9 percentage points to 38.7% compared to Q2 2024, indicating ongoing progress in margin expansion and profitability [1][2][5] - The company is focusing on diversification in industrial, medical, and aerospace/defense sectors to mitigate risks associated with transportation market fluctuations [4][7] Financial Performance - Non-GAAP free cash flow increased significantly from $15.0 million in Q2 2024 to $25.1 million in Q2 2025, showcasing strong cash generation capabilities [2][6] - Adjusted EBITDA margin rose to 23.0%, up 1.3 percentage points from the previous year, reflecting improved profitability metrics [2][5] - Revenue from the medical and aerospace/defense markets showed strong volume gains, while transportation revenue faced challenges due to softer demand in China and increased competition [7][8] Business Strategy - CTS has shifted its strategy to prioritize growth in industrial, medical, and aerospace/defense sectors, which helps offset risks from declining transportation sales [4] - The company emphasizes continuous innovation, disciplined cost management, and a strong pipeline of new program wins in targeted growth markets as key success factors [4] - Management is focused on M&A-driven growth and shareholder returns, with planned capital expenditures expected to be approximately 4% of sales for FY2025 [10] Outlook - CTS maintains its fiscal 2025 guidance, expecting GAAP net sales between $520 million and $550 million and non-GAAP adjusted diluted EPS of $2.20 to $2.35 [9] - Investors should monitor margin performance, customer concentration dilution, and the pace of end-market diversification, as these factors will be critical for future performance [11]